Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067

BACKGROUND: Treatment-free survival (TFS) characterizes disease control after discontinuation of immune checkpoint inhibitors (ICIs) until subsequent therapy or death. We previously evaluated TFS in a pooled analysis of the CheckMate 067 and CheckMate 069 trials of the ICIs nivolumab and ipilimumab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Regan, Meredith M, Mantia, Charlene M, Werner, Lillian, Tarhini, Ahmad A, Larkin, James, Stephen Hodi, F, Wolchok, Jedd, Postow, Michael A, Stwalley, Brian, Moshyk, Andriy, Ritchings, Corey, Re, Sandra, van Dijck, Wim, McDermott, David F, Atkins, Michael B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606772/
https://www.ncbi.nlm.nih.gov/pubmed/34799400
http://dx.doi.org/10.1136/jitc-2021-003743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606772/
https://www.ncbi.nlm.nih.gov/pubmed/34799400
http://dx.doi.org/10.1136/jitc-2021-003743

Ejemplares similares